Development and Characterization of MDR1 (

ATP Binding Cassette Transporter, Subfamily B / genetics Administration, Oral Animals Brain / metabolism CRISPR-Cas Systems / genetics Cytochrome P-450 CYP3A / analysis Digoxin / administration & dosage Female Gene Knockout Techniques / methods Intestine, Small / metabolism Kidney / metabolism Liver / metabolism Male Models, Animal RNA, Messenger / analysis Rats Rats, Sprague-Dawley Rats, Transgenic

Journal

Drug metabolism and disposition: the biological fate of chemicals
ISSN: 1521-009X
Titre abrégé: Drug Metab Dispos
Pays: United States
ID NLM: 9421550

Informations de publication

Date de publication:
02 2019
Historique:
received: 31 08 2018
accepted: 19 11 2018
pubmed: 28 11 2018
medline: 19 7 2019
entrez: 28 11 2018
Statut: ppublish

Résumé

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) technology is widely used as a tool for gene editing in rat genome site-specific engineering. Multidrug resistance 1 [MDR1 (also known as P-glycoprotein)] is a key efflux transporter that plays an important role not only in the transport of endogenous and exogenous substances, but also in tumor MDR. In this report, a novel MDR1 (

Identifiants

DOI: 10.1124/dmd.118.084277 PMID: 30478157
pubmed: 30478157
pii: dmd.118.084277
doi: 10.1124/dmd.118.084277
doi:

Substances chimiques

ATP Binding Cassette Transporter, Subfamily B 0
RNA, Messenger 0
Digoxin 73K4184T59
multidrug resistance protein 3 9EI49ZU76O
Cytochrome P-450 CYP3A EC 1.14.14.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-79

Informations de copyright

Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.

Auteurs

Chenmeizi Liang (C)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Junfang Zhao (J)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Jian Lu (J)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Yuanjin Zhang (Y)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Xinrun Ma (X)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Xuyang Shang (X)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Yongmei Li (Y)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Xueyun Ma (X)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Mingyao Liu (M)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.).

Xin Wang (X)

Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, People's Republic of China (C.L., J.Z., J.L., Y.Z., Xi.M., X.S., Y.L., Xu.M., M.L., X.W.); and Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, Texas (M.L.) xwang@bio.ecnu.edu.cn usxinwang@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Pompes ioniques › Transporteurs d'anions › Transporteurs d'anions organiques › Transporteurs d'anions organiques ATP-dépendants › Sous-famille B de transporteurs à cassette liant l'ATP › Development and Characterization of MDR1 (
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Development and Characterization of MDR1 (
questionsmedicales.fr › Eucaryotes › Animaux › Development and Characterization of MDR1 (
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Development and Characterization of MDR1 (
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › Development and Characterization of MDR1 (
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Hémoprotéines › Cytochromes › Cytochrome P-450 enzyme system › Famille-3 de cytochromes P450 › Cytochrome P-450 CYP3A › Development and Characterization of MDR1 (
questionsmedicales.fr › Glucides › Hétérosides › Glucosides cardiotoniques › Glucosides digitaliques › Digoxine › Development and Characterization of MDR1 (
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Ciblage de gène › Techniques de knock-out de gènes › Development and Characterization of MDR1 (
questionsmedicales.fr › Système digestif › Tube digestif › Intestins › Intestin grêle › Development and Characterization of MDR1 (
questionsmedicales.fr › Appareil urogénital › Voies urinaires › Rein › Development and Characterization of MDR1 (
questionsmedicales.fr › Système digestif › Foie › Development and Characterization of MDR1 (
questionsmedicales.fr › Techniques d'investigation › Modèles animaux › Development and Characterization of MDR1 (
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › Development and Characterization of MDR1 (
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Development and Characterization of MDR1 (
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rat Sprague-Dawley › Development and Characterization of MDR1 (
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Rats transgéniques › Development and Characterization of MDR1 (